Technology News and Research

RSS

ASU scientists develop versatile DNA reader to unlock DNA genetic code

Arizona State University scientists have come up with a new twist in their efforts to develop a faster and cheaper way to read the DNA genetic code. They have developed the first, versatile DNA reader that can discriminate between DNA's four core chemical components⎯the key to unlocking the vital code behind human heredity and health.

12 Feb 2010

Proving value a challenge for comparative effectiveness and pharmaceutical technologies

The Wall Street Journal reports that "an examination of one of the best-known examples of a comparative-effectiveness analysis shows how complicated such a seemingly straightforward idea can get" as officials look for savings in the health care system." One study, called Courage, "found that the most common heart surgery -- a $15,000 procedure that unclogs arteries using a small scaffold or stent -- usually yields no additional benefit when used with a cocktail of generic drugs in patients suffering from chronic chest pain."

12 Feb 2010

Siemens Healthcare renews strategic alliance with NextGen Healthcare Information Systems

Today, Siemens Healthcare announced it has renewed its strategic alliance with NextGen Healthcare Information Systems to deliver innovative ambulatory information technology (IT) solutions. More than 35 Siemens customers have already deployed NextGen Healthcare's ambulatory IT tools throughout their physician networks as a result of the relationship, formed to offer healthcare providers interoperable solutions that cross the care coordination gap between the acute and ambulatory environments.

12 Feb 2010

Researchers identify potential drug candidate that halts tumor growth

A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds to a molecular "switch" found in cancer cells and cancer-associated blood vessels to keep it in the "off" position.

12 Feb 2010

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

pSivida Corp. , a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its second quarter and six months ended December 31, 2009.

12 Feb 2010

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

Advanced Cell Technology, Inc. or “ACT” reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging. The research, which appears online (published-ahead-of- print) in the journal STEM CELLS by ACT and its collaborators at Stem International (SCRMI), Harvard Medical School, and the University of Illinois, compares a variety of replacement cell types derived from human iPS cells with their embryonic stem (ES) cell counterparts. The findings support the use of ACT’s single blastomere-derived human embryonic stem cell lines which do not display early aging.

12 Feb 2010

Mesa Laboratories reports fiscal third quarter results

Mesa Laboratories, Inc. today reported sales and earnings for both its fiscal third quarter and nine months ended December 31, 2009.

12 Feb 2010

HIE leaders convene to discuss prospect of healthcare delivery

Dr. David Kibbe, recognized healthcare futurist and Senior Advisor, American Academy of Family Physicians, headlined Medicity’s Customer Summit last week, which attracted the nation’s most progressive healthcare organizations engaged in health information exchange (HIE) across the largest ecosystem of connected providers nationwide.

12 Feb 2010

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).

12 Feb 2010

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."

12 Feb 2010

New screening system developed to discover molecules that block HCV life cycle

A newly designed system of identifying molecules for treating hepatitis C should enable scientists to discover novel and effective therapies for the dangerous and difficult-to-cure disease of the liver, says Zhilei Chen, a Texas A&M University assistant professor of chemical engineering who helped develop the screening system.

12 Feb 2010

Akron General Health System and McKesson announce strategic agreement to enhance patient care

Akron General Health System and McKesson today announced a strategic agreement that expands the hospital’s ongoing initiative to boost patient safety, improve quality and enhance care coordination among healthcare providers in northeast Ohio.

12 Feb 2010

iTech Medical signs manufacturing agreement with Thought Technology for MPR technology

iTech Medical, an information technology company, announced today that it has signed an exclusive, three-year manufacturing agreement with Thought Technology Ltd. of Montreal, Quebec for the Company’s proprietary Muscle Pattern Recognition (MPR) technology.

12 Feb 2010

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.

11 Feb 2010

FDA grants approval for Abbott's antiretroviral medication Norvir

Abbott announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir ® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.

11 Feb 2010

Alcon reports 2009 fourth quarter results

Alcon, Inc. reported that global sales rose 14.5 percent to $1.72 billion for the fourth quarter of 2009, or an 8.5 percent increase excluding the impact of foreign exchange fluctuations. Reported net earnings for the fourth quarter of 2009 grew 8.0 percent to $458 million, or $1.51 per diluted share.

11 Feb 2010

Cambridge Heart submits 510(k) application for Microvolt T-wave Alternans OEM Module

Cambridge Heart, Inc., today announced that the Company has completed the development phase of its Microvolt T-wave Alternans (MTWA) OEM Module, and has submitted a 510(k) application for regulatory approval with the U.S. Food and Drug Administration (FDA). The module is the centerpiece of the Company’s new business model that involves partnering with leading stress test equipment manufacturers to broaden the distribution and use of MTWA technology.

11 Feb 2010

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008.

11 Feb 2010

Boston Scientific combines Cardiovascular Group and Cardiac Rhythm Management Group

Boston Scientific Corporation today announced a series of management changes and restructuring initiatives designed to strengthen the Company and position it for long-term success.

11 Feb 2010

Winter Sports: Tips on proper training, and prevention of injuries and concussions

According to the Centers for Disease Control and Prevention, 46 percent of children admitted to trauma centers for winter sports injuries have been diagnosed with a head injury – the majority of them from snowboarding, sledding, skiing, ice skating or ice hockey. Pediatric sports medicine is a growing field and is a direct response to how active today’s children are in competitive and recreational sports.

11 Feb 2010

Technology News and Research

ASU scientists develop versatile DNA reader to unlock DNA genetic code

Proving value a challenge for comparative effectiveness and pharmaceutical technologies

Siemens Healthcare renews strategic alliance with NextGen Healthcare Information Systems

Researchers identify potential drug candidate that halts tumor growth

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

Mesa Laboratories reports fiscal third quarter results

HIE leaders convene to discuss prospect of healthcare delivery

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

New screening system developed to discover molecules that block HCV life cycle

Akron General Health System and McKesson announce strategic agreement to enhance patient care

iTech Medical signs manufacturing agreement with Thought Technology for MPR technology

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

FDA grants approval for Abbott's antiretroviral medication Norvir

Alcon reports 2009 fourth quarter results

Cambridge Heart submits 510(k) application for Microvolt T-wave Alternans OEM Module

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Boston Scientific combines Cardiovascular Group and Cardiac Rhythm Management Group

Winter Sports: Tips on proper training, and prevention of injuries and concussions

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News